VIDEO: Ixo-vec may reduce need for anti-VEGF injections in wet AMD
Click Here to Manage Email Alerts
In this video, Donald J. D’Amico, MD, discusses data from the phase 2 LUNA trial of Ixo-vec intravitreal gene therapy for neovascular age-related macular degeneration.
The results, presented at the American Society of Retina Specialists annual meeting, showed that after 26 weeks, the frequency of additional annualized anti-VEGF injections was reduced by more than 90%.
“Of course, there is a need to evaluate these patients carefully for either supplemental regular anti-VEGF injections if they show signs of worsening and/or secondary inflammatory events,” D’Amico, professor and chair of the Israel Englander department of ophthalmology at Weill Cornell Medical College, said.
A number of anti-inflammatory strategies were employed in the study, including prednisone and topical medications.
“Gene therapy with this compound appears quite promising and has demonstrated very positive efficacy results,” he said.
Reference:
- Wykoff C, et al. Ixoberogene soroparvovec (Ixo-vec) IVT gene therapy for neovascular AMD: First-time 26-week interim analysis results from the phase 2 LUNA study. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.
Collapse
Healio Interviews
Click Here to Manage Email Alerts